In the third segment of the Radioligands session from Uromigos Live 2024, the panel discusses two significant trials in metastatic hormone-sensitive prostate cancer, focusing on the use of lutetium PSMA therapy. The panel examines the challenges of determining proper dosing, feasibility, and quality-of-life measures while also considering the evolving landscape of prostate cancer treatment.
Uromigos Live 2024 Radioligands Part 3: UpFront PSMA Results from ESMO 2024
By Brian Rini, MD, FASCO, Karen Autio, MD, Michael Morris, MD, Gary T. Smith, MD, Tanya Dorff, MD - Last Updated: October 29, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.